Bacterial Conjunctivitis
Conditions
Brief summary
The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
Interventions
Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Sponsors
Study design
Eligibility
Inclusion criteria
* Clinically diagnosed with bacterial conjunctivitis
Exclusion criteria
* Signs and/or symptoms of conjunctivitis for more than 96 hours * Signs and/or symptoms suggestive of fungal, viral, or allergic conjunctivitis * Clinical diagnosis of chlamydia in either eye
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6 | Day 6 | Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients With Clinical Improvement of Ocular Signs at Day 6 | Day 6 | Percentage of patients with clinical improvement of ocular signs at Day 6 based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe), defined as a decrease (improvement) from Day 1 (Baseline) in the total score of conjunctival hyperemia and mucopurulent discharge (pus),with no increase (worsening) from Day 1 (Baseline) in either individual variable in the study eye. |
| Percentage of Patients With Microbiological Cure at Day 6 | Day 6 | Percentage of patients with microbiological cure, defined such that all bacteria present in the study eye at Day 1 (Baseline) are eradicated (or absent) at Day 6 based on a Classification of Microbial Response. (Eradication=pathogen is absent in follow-up culture; Reduction=pathogen is reduced from baseline below threshold count in follow-up culture; Persistence=pathogen reduced from baseline but is above or equal to threshold count in follow-up culture; and Proliferation=pathogen has increased in count from baseline in follow-up culture) |
| Percentage of Patients With Clinical Improvement of Ocular Symptoms at Day 6 | Day 6 | Percentage of patients with clinical improvement of ocular symptoms at Day 6, defined as a decrease (improvement) from Day 1 (Baseline) in the total score of itching and tearing (each on 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe), with no increase (worsening) from Day 1 (Baseline) in any individual score in the study eye diagnosed with bacterial conjunctivitis |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Gatifloxacin 0.5% Eye Drops Gatifloxacin 0.5% eye drops | 287 |
| Placebo Eye Drops Placebo eye drops | 291 |
| Total | 578 |
Baseline characteristics
| Characteristic | Gatifloxacin 0.5% Eye Drops | Placebo Eye Drops | Total |
|---|---|---|---|
| Age, Customized 1-18 years | 123 participants | 123 participants | 246 participants |
| Age, Customized 19-65 years | 126 participants | 141 participants | 267 participants |
| Age, Customized >65 years | 38 participants | 27 participants | 65 participants |
| Sex: Female, Male Female | 161 Participants | 172 Participants | 333 Participants |
| Sex: Female, Male Male | 126 Participants | 119 Participants | 245 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 14 / 288 | 13 / 289 |
| serious Total, serious adverse events | 0 / 288 | 1 / 289 |
Outcome results
Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).
Time frame: Day 6
Population: Modified Intent to Treat; defined as all randomized patients who were culture positive at baseline meaning the culture of the eye grew bacteria. (Note: The Day 6 analysis included all Day 6 visit data, regardless of whether it was collected on Day 6 or on a later day).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Gatifloxacin 0.5% Eye Drops | Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6 | 74.9 Percentage of Patients |
| Placebo Eye Drops | Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6 | 65.2 Percentage of Patients |
Percentage of Patients With Clinical Improvement of Ocular Signs at Day 6
Percentage of patients with clinical improvement of ocular signs at Day 6 based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe), defined as a decrease (improvement) from Day 1 (Baseline) in the total score of conjunctival hyperemia and mucopurulent discharge (pus),with no increase (worsening) from Day 1 (Baseline) in either individual variable in the study eye.
Time frame: Day 6
Population: Modified Intent to Treat; defined as all randomized patients who were culture positive at baseline meaning the culture of the eye grew bacteria. (Note: The Day 6 analysis included all Day 6 visit data, regardless of whether it was collected on Day 6 or on a later day).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Gatifloxacin 0.5% Eye Drops | Percentage of Patients With Clinical Improvement of Ocular Signs at Day 6 | 97.0 Percentage of Patients |
| Placebo Eye Drops | Percentage of Patients With Clinical Improvement of Ocular Signs at Day 6 | 96.2 Percentage of Patients |
Percentage of Patients With Clinical Improvement of Ocular Symptoms at Day 6
Percentage of patients with clinical improvement of ocular symptoms at Day 6, defined as a decrease (improvement) from Day 1 (Baseline) in the total score of itching and tearing (each on 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe), with no increase (worsening) from Day 1 (Baseline) in any individual score in the study eye diagnosed with bacterial conjunctivitis
Time frame: Day 6
Population: Modified Intent to Treat; defined as all randomized patients who were culture positive at baseline meaning the culture of the eye grew bacteria. (Note: The Day 6 analysis included all Day 6 visit data, regardless of whether it was collected on Day 6 or on a later day).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Gatifloxacin 0.5% Eye Drops | Percentage of Patients With Clinical Improvement of Ocular Symptoms at Day 6 | 85.5 Percentage of Patients |
| Placebo Eye Drops | Percentage of Patients With Clinical Improvement of Ocular Symptoms at Day 6 | 82.2 Percentage of Patients |
Percentage of Patients With Microbiological Cure at Day 6
Percentage of patients with microbiological cure, defined such that all bacteria present in the study eye at Day 1 (Baseline) are eradicated (or absent) at Day 6 based on a Classification of Microbial Response. (Eradication=pathogen is absent in follow-up culture; Reduction=pathogen is reduced from baseline below threshold count in follow-up culture; Persistence=pathogen reduced from baseline but is above or equal to threshold count in follow-up culture; and Proliferation=pathogen has increased in count from baseline in follow-up culture)
Time frame: Day 6
Population: Modified Intent to Treat; defined as all randomized patients who were culture positive at baseline meaning the culture of the eye grew bacteria. (Note: The Day 6 analysis included all Day 6 visit data, regardless of whether it was collected on Day 6 or on a later day).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Gatifloxacin 0.5% Eye Drops | Percentage of Patients With Microbiological Cure at Day 6 | 89.2 Percentage of Patients |
| Placebo Eye Drops | Percentage of Patients With Microbiological Cure at Day 6 | 61.4 Percentage of Patients |
Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye up to Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe). (Note: The Up to Day 6 analysis included all data up to the Day 6 time point but excluded any Day 6 visit data that was collected after the Day 6 time point).
Time frame: 6 Days
Population: Modified Intent to Treat; defined as all randomized patients who were culture positive at baseline meaning the culture of the eye grew bacteria. (Note: The Up to Day 6 analysis included all data up to the Day 6 time point but excluded any Day 6 visit data that was collected after the Day 6 time point).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Gatifloxacin 0.5% Eye Drops | Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6 | 64.1 Percentage of Patients |
| Placebo Eye Drops | Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6 | 50.0 Percentage of Patients |